Groowe Groowe / Newsroom / CUE
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CUE News

Cue Biopharma, Inc.

Ric Burns' Acclaimed NEW YORK: A DOCUMENTARY FILM Returns with Two New Films September 21st and 22nd On PBS

prnewswire.com
AMX GOOG CMCSA IBM MSFT NVDA INTC META AMZN NFLX ABNB UBER LYFT TSLA GM F RIVN NIO XPEV LI PLTR SNOW CRM ADBE GOOGL MSCI SPGI BKNG EXPE MAR H WYNN LVS MGM CHTR VZ T QCOM AMD MU AMAT ASML TXN NXPI ON ADI LRCX KLAC MRVL WDC SE BABA JD PDD BIDU BILI IQ VIPS HTHT NTES EDU BEKE RMAX Z HOFT PG KO PEP MCD SBUX YUM CMG WEN CAKE BJRI EAT DRI BLMN TH QSR SONO BBY WMT TGT HD LOW COST TJX ROST M KSS URBN ANF AEO LULU NKE UA CROX RL PVH TPR CPRI KHC GIS CL EL ORCL SAP ACN HPQ DELL CSCO INTU PYPL AXP V MA JPM BAC WFC C MS GS SCHW RJF LPLA BEN IVZ AB PGR ALL TRV CB UNM MET PRU AIG LNC GL CCI AMT EQIX DLR COR NTAP STX WD CDNS SNPS QTRX REGN GILD AMGN BMY ABBV LLY PFE MRK JNJ BIIB VRTX ALKS AZN SNY NVS CRSP EDIT NTLA BNTX MRNA EXAS ILMN ROKU CRWD COIN MARA RIOT FTFT BTBT CLSK HUT GLXY NNDM IONQ RIG NVCR CRBU ACRS APLS AXSM CLDX CRBP CUE CYTK DASH GRWG PLUG FCEL BE NEE DUK SO EXC SRE PCG

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

prnewswire.com
CUE

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

globenewswire.com
CUE

Form 8-K

sec.gov
CUE

Form 8-K

sec.gov
CUE

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

globenewswire.com
CUE

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

globenewswire.com
JNJ BNTX GMAB IMUX INO PDSB AZN GSK MRK BIIB EXEL REGN CUE IOBT RAPT PRE

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

globenewswire.com
JNJ BNTX CUE GMAB IMPP INO AZN GSK MRK BMY EXEL REGN PDSB IOVA RPTX

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

globenewswire.com
CUE

Form 8-K

sec.gov
CUE